Orna Almog, PhD
Galila Agam, PhD
Ben-Gurion University
Beer-Sheva,Israel
Will determine the three-dimensional structure of calbindin and its interaction with inositol monophosphatase. Will also design peptides that mimic the stimulatory effects of calbindin on inositol monophastase.

Clare Beasley, PhD
William Honer, MD
University of British Columbia
Vancouver,Canada
Will study levels of myelin-associated proteins, post-translational modifications of some of these proteins, and the density of oligodendrocytes in postmortem specimens from the Stanley Neuropathology Consortium.

Cecile Beguin, PhD, et al.
Harvard Medical School
Belmont, MA
Will investigate the neurochemical and behavioral effects of several kappa-opiate receptor agonists as treatments for mood disorders.

Haim Einat, PhD, et al.
University of Minnesota
Duluth, MN
Will test behavioral and cellular effects of rapamycin in animal models of mood disorders. Rapamycin is an immunosuppressant and antibiotic that is a potential inhibitor of mTOR.

S. H. Fatemi, MD, PhD
University of Minnesota
Minneapolis, MN
Will determine levels of the various isoforms of phosphodiesterase protein and mRNAs in rats treated with antipsychotics,-mood stabilizers, and antidepressants. Will also determine levels of phosphodiesterases in postmortem brain samples from the Stanley Neuropathology Consortium.

Marlon Quinones, MD
Jair Soares, MD
University of Texas Health Science Center at San Antonio
San Antonio, TX
Will perform a proteomic investigation of immune- and infectious disease–related markers in bipolar disorder.

Takeshi Sakurai, MD, PhD
Joseph Buxbaum, PhD
Mount Sinai School of Medicine
New York, NY
Using postmortem samples from the Stanley and Mt. Sinai collections, will measure levels of oligodendrocyte and myelin related genes and produce knockout mice for many of these genes.

Robert Sapolsky, PhD
Stanford University
Palo Alto, CA
Will study the effects of Toxoplasma gondii infection in rats on dopamine synthesis, dopamine catabolism, and dopamine-receptor function.

Akira Sawa, MD, PhD
Robert Yolken, MD
Johns Hopkins University
Baltimore, MD
Will test the interaction of DISC-1 with promyelocytic leukemia protein and the effects on this interaction of cytomegalovirus infection.

Yasuhiro Suzuki, PhD
Virginia Polytechnic Institute and State University
Blacksburg, VA
Mice with quiescent Toxoplasma gondii infection will have the infection reactivated with anti-IFN-? antibody, and histologic and serologic data will be collected. Infected mice will also be re-infected with the parasite, and similar data will be collected. The study is designed to help understand if the increased prevalence of antibodies to Toxoplasma gondii in schizophrenia is a primary cause of the disease or a secondary result of having the disease.

Gao Hua Wang, MD, PhD, et al.
Renmin Hospital of Wuhan University
Wuhan, Hubei,China
Will determine the prevalence of Toxoplasma gondii seropositivity in 10,000 college freshman and follow this cohort to determine the relationship between Toxoplasma gondii infection and the development of schizophrenia and bipolar disorder.

L. Trevor Young, MD, PhD
Jun-Feng Wang, MD, PhD
Centre for Addiction and Mental Health
University of Toronto
Toronto, Ontario,Canada
Using postmortem samples from the Stanley collection, will measure RNA and protein levels of mitochondrial electron transport chain proteins and seek evidence of oxidative damage to brain lipids and proteins.

Fan Zhu, PhD, et al.
Wuhan University
Wuhan, Hubei,China
Will study the prevalence of human endogenous retrovirus infection inChina and its relationship to the clinical features of schizophrenia.